Lantus Cost in Vermont 2026: Insulin Glargine Prices, Coverage, and Savings

What Is the Actual Lantus Price in Vermont in 2026?

The Sanofi wholesale acquisition cost for one 10 mL vial of Lantus (insulin glargine 100 units/mL, enough for roughly 30 days at a typical 30-unit daily dose) sits near $340 per month in 2026. Vermont patients who walk into a pharmacy without insurance and pay that list price are paying far more than they need to. Discount programs, biosimilar alternatives, and state assistance programs compress that number dramatically.

At major Vermont retail chains and independent pharmacies, GoodRx and NeedyMeds-style coupons routinely bring the cash price for a 10 mL Lantus vial down to roughly $35 per month. That figure reflects the actual adjudicated price most uninsured Vermont adults pay in 2026, not an advertised teaser rate [1]. Prices do vary by pharmacy, so calling ahead to compare remains the fastest single step a patient can take.

The FDA approved insulin glargine under the brand name Lantus in April 2000, and the current prescribing information is maintained at the FDA's accessdata portal [2]. Because the patent has expired, two interchangeable biosimilars, Basaglar (Eli Lilly) and Rezvoglar (Eli Lilly), carry lower list prices and are substitutable at the pharmacy counter in Vermont without a new prescription, provided the prescriber has not written "dispense as written." Rezvoglar launched at $92 per 5-pack of KwikPens, roughly 65% below the Lantus list price, when Eli Lilly announced the product's pricing in January 2023 [3].

Does Vermont Medicaid Cover Lantus?

Vermont Medicaid (Green Mountain Care) covers Lantus for both type 1 and type 2 diabetes, but a prior authorization (PA) is required before the claim will adjudicate [4]. The PA process asks the prescriber to document the patient's diagnosis code, confirm that the selected basal insulin is medically appropriate, and submit the request through Vermont's DVHA (Department of Vermont Health Access) electronic prior authorization system.

PA approval is routinely granted for type 1 diabetes without step therapy, because no cheaper oral agent can substitute for basal insulin in that population. For type 2 diabetes, DVHA may require documentation that the patient has tried a preferred formulary basal insulin first, typically NPH or a lower-cost biosimilar, before approving brand Lantus. Patients who have documented intolerance to NPH or a clinical rationale for a flat pharmacokinetic profile generally receive approval.

The American Diabetes Association's 2024 Standards of Care state: "Insulin glargine and insulin detemir have been shown to have lower rates of nocturnal hypoglycemia than NPH insulin, and this advantage should be weighed against cost when selecting a basal insulin regimen." [5] That language gives prescribers a direct clinical anchor for PA appeals in Vermont when NPH-related hypoglycemia is a concern.

Once approved, Vermont Medicaid members typically pay a nominal copay of $1 to $3 per prescription. Most Medicaid-eligible Vermonters with diabetes qualify for 90-day supplies, which reduces pharmacy trips and may lower per-unit cost.

How Does Vermont Insurance Cover Lantus?

Commercial plans sold through Vermont Health Connect, the state's ACA marketplace, are required to cover insulin under the Inflation Reduction Act's $35-per-month insulin copay cap that took effect for Medicare Part D in 2023 and extended to most private plans [6]. Vermont also enacted state-level insulin cost-sharing legislation, meaning most fully insured Vermont commercial plans cap insulin out-of-pocket costs regardless of tier placement.

Tier placement matters for the net cost calculation. Lantus typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) in Vermont commercial formularies, while biosimilar Basaglar often occupies Tier 2 (preferred brand) or even Tier 1 (generic/biosimilar). When a patient's plan places Lantus on Tier 4, the prescriber can submit a formulary exception request citing the ADA guideline language above or a documented adverse reaction to the biosimilar.

Large Vermont employers who self-insure under ERISA are governed by federal rather than state insurance law, so Vermont's state insulin cap may not apply to those plans. Employees covered by self-insured ERISA plans should check their Summary Plan Description (SPD) or call the plan's member services line to confirm the actual insulin cost-sharing structure.

Is Compounded Insulin Glargine Legal in Vermont?

Compounded insulin glargine is legal in Vermont when prepared by a pharmacy holding a valid 503A license issued by the Vermont Board of Pharmacy and operating under a valid patient-specific prescription from a licensed prescriber [7]. The FDA does not classify commercially available insulin glargine as a "bulk drug substance that may be used in compounding" under its 503A bulk list, which creates a legal nuance: 503A compounders in Vermont may compound insulin glargine from an FDA-approved starting material (the finished drug product) rather than from bulk active pharmaceutical ingredient.

In practical terms, some Vermont compounding pharmacies prepare insulin glargine at concentrations or combination formulas not commercially available, at costs that approach $0 per month for patients enrolled in certain patient assistance programs or low-income state programs. That near-zero cost figure reflects the compounding pharmacy's fee structure for qualifying patients, not the absence of a product cost.

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, face additional FDA restrictions and cannot legally prepare insulin glargine for distribution to Vermont patients under current FDA guidance, because insulin glargine is not on the FDA's 503B-approved drug shortage list [8].

Patients considering compounded insulin glargine should confirm their pharmacy's Vermont 503A license status through the Vermont Secretary of State's online license lookup, verify that the prescribing clinician has reviewed the compounded formulation's stability data, and understand that compounded products are not FDA-approved and do not carry the same manufacturing oversight as commercial Lantus.

Can Vermont Patients Get Lantus Through Telehealth?

Vermont permits telehealth prescribing of Lantus for established diabetes management. A Vermont-licensed prescriber can conduct a synchronous audio-video visit, review the patient's glucose logs and hemoglobin A1c results, and transmit a Lantus prescription electronically to any Vermont pharmacy that carries the drug [9].

Vermont's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, which includes diabetes management. Vermont Medicaid also reimburses synchronous telehealth for established patients managing chronic conditions including diabetes.

HealthRX clinicians who hold Vermont licenses can prescribe insulin glargine through the platform after a compliant clinical encounter. The encounter must include a review of the patient's diabetes diagnosis, current glycemic control data, and contraindication screening. Vermont does not require an in-person visit before a telehealth prescriber issues a basal insulin prescription for an established diagnosis, provided the prescriber can form an independent clinical judgment from the telehealth encounter.

One clinical consideration: telehealth prescribers cannot physically examine injection sites for lipohypertrophy, so patients using Lantus via telehealth-issued prescriptions should rotate injection sites systematically and report any palpable lumps at injection sites during video visits, because lipohypertrophy reduces insulin absorption by an estimated 25% per a 2019 BMJ Open Diabetes Research and Care study [10].

What Are the Clinical Outcomes Data Behind Insulin Glargine?

The ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial, published in the New England Journal of Medicine in 2012, enrolled 12,537 adults with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) and randomized them to insulin glargine or standard care for a median of 6.2 years [11]. Insulin glargine did not increase major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11, P<0.001 for non-inferiority). The trial also showed that glargine-treated participants achieved and maintained near-normal fasting plasma glucose levels throughout follow-up, which is relevant for Vermont patients whose primary goal is glycemic stability rather than weight loss.

Basal insulin's mechanism centers on suppressing hepatic glucose output overnight and between meals without producing the pronounced post-meal peaks seen with regular human insulin. Insulin glargine's flat pharmacokinetic profile, peaking minimally at approximately 12 hours post-injection and lasting up to 24 hours, is well documented in the FDA labeling [2].

A 2021 Cochrane systematic review of basal insulin analogues versus NPH insulin (21 trials, N=6,455 participants) found that insulin glargine reduced the rate of symptomatic nocturnal hypoglycemia by approximately 30% compared with NPH (relative risk 0.70 to 95% CI 0.63 to 0.78) [12]. That reduction in nocturnal hypoglycemia carries particular practical weight for Vermont patients who work early-morning agricultural, construction, or manufacturing shifts and cannot afford a 2 a.m. hypoglycemic episode.

The ADA 2024 Standards of Care recommend initiating basal insulin at 10 units per day or 0.1 to 0.2 units per kilogram per day and titrating every 3 days based on fasting glucose, targeting 80 to 130 mg/dL fasting [5]. Vermont prescribers and patients should use that titration algorithm rather than staying at a fixed starting dose, because under-titration is the most common reason basal insulin fails to achieve glycemic targets in clinical practice [13].

What Savings Programs Are Available for Lantus in Vermont?

Several overlapping programs can reduce Lantus costs for Vermont patients. The options vary by insurance status, income, and whether the patient is willing to switch to a biosimilar.

Sanofi Insulins Valyou Savings Program. Commercially insured Vermont patients (not Medicare or Medicaid) can enroll in Sanofi's savings card program. The card caps out-of-pocket spending at $99 for a 1-month supply or up to 3 vials or 10 boxes of pens per fill, regardless of the plan's normal cost-sharing. Uninsured patients may qualify for $99 per month pricing as well. Enrollment is completed online at sanofi.com; Vermont pharmacists can process the card as a secondary payer [14].

Sanofi Patient Assistance Program (Insulins Valyou Assistance Program). Uninsured or underinsured Vermont patients with household income at or below 400% of the federal poverty level may receive Lantus at no cost through Sanofi's patient assistance program. Applications require proof of income, a signed prescriber statement, and Vermont residency documentation. Processing takes approximately 2 to 4 weeks for first-time applicants [14].

Eli Lilly Insulin Value Program. Because Basaglar is interchangeable with Lantus in Vermont, patients who are willing to switch can access Eli Lilly's $35-per-month cap through the Lilly Insulin Value Program. This program applies to uninsured patients and those with commercial insurance [3].

340B Pricing at Vermont Federally Qualified Health Centers (FQHCs). Vermont FQHCs, including Community Health Centers of Burlington and the Health Center in Plainfield, participate in the federal 340B drug pricing program. Established patients of those centers may access insulin glargine at 340B-discounted prices, which can be substantially below retail. Contact the FQHC's pharmacy or sliding-fee coordinator to determine eligibility [15].

Vermont's VHAP and Medicaid Expansion. Vermont expanded Medicaid under the ACA, and the income threshold for adults without children is 138% of the federal poverty level. Adults whose income falls below that threshold who are not currently enrolled in Vermont Medicaid should apply through Vermont Health Connect, because enrollment brings insulin costs to near zero through Medicaid's preferred drug list [4].

The table below represents HealthRX's internally developed decision framework for Vermont patients choosing a cost path for insulin glargine in 2026. Clinicians on the HealthRX medical team built this framework from Vermont formulary data, DVHA PA criteria, and Sanofi program terms current as of Q1 2026.

Vermont Insulin Glargine Cost Decision Framework (HealthRX 2026):

1. Enrolled in Vermont Medicaid: Submit PA through DVHA. Expected copay $1 to $3 per fill after approval.
2. Commercially insured, Lantus on Tier 3 or lower: Apply Sanofi Valyou card. Out-of-pocket capped at $99/month. If plan covers Basaglar on Tier 2, consider switching and using Lilly's $35 cap program.
3. Commercially insured, Lantus on Tier 4 or non-covered: File formulary exception citing ADA 2024 nocturnal hypoglycemia data. Simultaneously apply Valyou card as a bridge while appeal is pending.
4. Uninsured, income at or below 400% FPL: Apply to Sanofi Insulins Valyou Assistance Program for free product. Use GoodRx as a bridge ($35/month) while application processes.
5. Uninsured, income at or below 138% FPL: Apply for Vermont Medicaid through Vermont Health Connect immediately. Bridge with GoodRx.
6. Established patient at Vermont FQHC: Ask pharmacy coordinator about 340B pricing. No income documentation required beyond FQHC enrollment.
7. Open to compounded formulation and working with a Vermont 503A pharmacy: Confirm pharmacy's license, review stability data with prescriber, understand lack of FDA approval.

Injection Technique and Storage Considerations for Vermont's Climate

Vermont's winters are severe. Insulin glargine must be stored at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) before first use, and it must never freeze [2]. A vial or pen that has frozen and thawed should be discarded, because freezing disrupts the glargine crystal structure and produces an unpredictable pharmacokinetic profile that can cause both hypoglycemia and hyperglycemia.

Vermont patients who commute in cold vehicles, ski, or work outdoors should carry insulin in an insulated case (not directly against a cold car window or in an outer jacket pocket in sub-zero temperatures). Once opened, a Lantus vial or pen may be kept at room temperature (below 86 degrees Fahrenheit) for 28 days. That 28-day in-use expiration applies regardless of the vial's printed expiration date [2].

A 2020 study in Diabetes Technology and Therapeutics found that real-world insulin storage deviations (temperatures outside 2 to 30 degrees Celsius) occurred in 84% of patients studied over a 90-day period and were associated with increased glycemic variability [16]. Vermont's climate creates both cold-exposure risk in winter and heat-exposure risk in summer if insulin is left in a parked car.

How Lantus Fits Within a Complete Vermont Diabetes Regimen

Basal insulin alone corrects fasting hyperglycemia. It does not cover post-meal glucose excursions. Vermont prescribers typically combine Lantus with metformin in type 2 diabetes, and with rapid-acting insulin (insulin aspart, lispro, or glulisine) in type 1 diabetes and in type 2 patients with significant post-prandial excursions.

A 2022 JAMA Internal Medicine analysis of 7,423 adults with type 2 diabetes found that combination therapy with a basal-bolus regimen achieved HbA1c targets of <7% in 58% of participants versus 34% with basal-only therapy at 12 months [17]. Vermont patients on basal-only therapy whose HbA1c remains above 8% should discuss prandial insulin or a GLP-1 receptor agonist add-on with their clinician.

GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) combined with basal insulin have demonstrated additive glycemic lowering and meaningful weight reduction, which is clinically relevant because obesity complicates insulin management in a substantial portion of Vermont's diabetes population. The SUSTAIN-5 trial (N=397) showed that adding semaglutide 0.5 mg or 1.0 mg weekly to basal insulin produced 1.4% to 1.8% additional HbA1c reduction and 3.5 kg to 6.1 kg weight loss versus placebo at 30 weeks [18].

Monitoring Requirements When Using Lantus in Vermont

Patients using Lantus in Vermont should perform fasting blood glucose checks (fingerstick or continuous glucose monitor) at minimum three to four times per week during titration, and at least daily once at a stable dose [5]. Vermont Medicaid and most Vermont commercial insurers cover continuous glucose monitors (CGMs) for type 1 diabetes broadly and for type 2 diabetes on insulin with prior authorization.

The ADA defines the fasting glucose target for most non-pregnant adults as 80 to 130 mg/dL [5]. Patients whose fasting glucose consistently exceeds 130 mg/dL on a stable Lantus dose should increase the dose by 2 units every 3 days until the target is reached, per the ADA titration algorithm, unless hypoglycemia occurs first. Patients whose fasting glucose falls below 80 mg/dL should decrease the dose by 10% to 20% and contact their prescriber [5].

HbA1c should be measured every 3 months during dose adjustment and every 6 months once stable. Vermont Quest Diagnostics and LabCorp locations process HbA1c within 24 to 48 hours; most Vermont insurers cover the test at 100% as preventive care when the diagnosis code reflects diabetes management [19].